Last reviewed · How we verify
EBV-specific cytotoxic T lymphocytes
EBV-specific cytotoxic T lymphocytes stimulate the immune system to target and kill Epstein-Barr virus-infected cells.
EBV-specific cytotoxic T lymphocytes stimulate the immune system to target and kill Epstein-Barr virus-infected cells. Used for Epstein-Barr virus-associated diseases.
At a glance
| Generic name | EBV-specific cytotoxic T lymphocytes |
|---|---|
| Also known as | EBV-specific cytotoxic T lymphocytes 1 x 10e8 cells/m2 IV |
| Sponsor | Baylor College of Medicine |
| Drug class | Cytotoxic T lymphocyte |
| Target | Epstein-Barr virus-infected cells |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This is achieved through the activation of cytotoxic T lymphocytes, which are a type of immune cell that can recognize and destroy infected cells. The EBV-specific cytotoxic T lymphocytes are engineered to recognize and target cells infected with the Epstein-Barr virus, thereby reducing the viral load and potentially treating associated diseases.
Approved indications
- Epstein-Barr virus-associated diseases
Common side effects
- Fever
- Fatigue
- Headache
Key clinical trials
- Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (PHASE1)
- EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders (PHASE1, PHASE2)
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (PHASE1)
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy (PHASE3)
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases (PHASE2)
- A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma (PHASE1, PHASE2)
- TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC (PHASE1)
- Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EBV-specific cytotoxic T lymphocytes CI brief — competitive landscape report
- EBV-specific cytotoxic T lymphocytes updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI